The side effects observed with the administration of Krsstor® are usually only slightly expressed and pass on their own.As with other inhibitors of HMG-CoA reductase, the incidence of side effects is mainly dose-dependent.
The frequency of undesirable effects is as follows:
often (> 1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (> 1/10000, <1/1000); very rarely (<1/10000), frequency, unspecified (can not be calculated from available data).
The immune system
Rarely: hypersensitivity reactions, including angioedema
Endocrine system
Often: diabetes mellitus type 2
From the central nervous system
Often: headache, dizziness
From the side of the digestive tract
Often: constipation, nausea, abdominal pain
Rarely: pancreatitis
From the skin
Infrequently: itching, rash, urticaria
From the side of the musculoskeletal system
Often: myalgia
Rarely: Myopathy (including myositis), rhabdomyolysis
Other
Often: asthenic syndrome
From the side of the urinary system
Patients receiving Crestor® can be diagnosed with proteinuria. Changes in the amount of protein in the urine (from absence or trace amounts to ++ or more) are observed in less than 1% of patients receiving 10-20 mg of the drug, and about 3% of patients,
receiving 40 mg of the drug.A slight change in the amount of protein in the urine was noted with a dose of 20 mg. In most cases, proteinuria decreases or disappears during therapy and does not indicate the occurrence of acute or progressive
existing kidney disease.
From the side of the locomotor system apparatus
When Krestor® was used in all dosages and, in particular, when taking doses of the drug in excess of 20 mg, the following effects on the musculoskeletal system were reported: myalgia, myopathy (including myositis), in rare cases - rhabdomyolysis with or without acute renal failure her. A dose-related increase in activity of creatine phosphokinase (CK) is observed in a small number of patients taking rosuvastatin. In most cases, it was insignificant, asymptomatic and temporary. In the case of increased activity of CK (more than 5 times compared with the upper limit of the norm) therapy should be suspended (see section "Special instructions").
From the side of the liver
With the use of rosuvastatin, a dose-dependent increase in the activity of "hepatic" transaminases in a small number of patients is observed.In most cases, it is insignificant, asymptomatic and temporary.
Laboratory indicators
When using the drug Krestor, the following changes in laboratory parameters were also observed: an increase in the concentration of glucose, bilirubin, activity of gamma-
glutamyltranspeptidase, alkaline phosphatase, thyroid dysfunction.
Postmarketing application
The following side effects have been reported in the post-marketing application of Crestor®:
On the part of the hematopoiesis system
Unspecified frequency: thrombocytopenia
From the side of the digestive tract
Very rarely: jaundice, hepatitis
Rarely: increased activity of "liver" transaminases
Unspecified frequency: diarrhea
From the side of the musculoskeletal system
Very rarely: arthralgia
Unspecified frequency: immunosupplemented necrotizing myopathy
From the central nervous system
Very rare: loss or loss of memory
Unspecified frequency: peripheral neuropathy
From the respiratory system
Unspecified frequency: cough, dyspnea
From the side of the urinary system
Very rare: hematuria
From the skin and subcutaneous fat
Unspecified frequency: Stevens-Johnson syndrome
From the reproductive system and breast
Unspecified frequency: gynecomastia
Other
Unspecified frequency: peripheral edema
Some statins reported the following side effects: depression, sleep disorders, including insomnia and nightmarish dreams, sexual dysfunction, hyperglycemia, increased concentrations of glycosylated hemoglobin. Single cases of interstitial lung disease have been reported, especially with prolonged use of drugs (see section "Special instructions").